{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["HDAC", "Hepatocellular carcinoma", "Potassium deprivation", "Sorafenib", "TXNIP"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36351536", "DateCompleted": {"Year": "2023", "Month": "09", "Day": "04"}, "DateRevised": {"Year": "2023", "Month": "09", "Day": "12"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "11", "Day": "09"}], "Language": ["eng"], "ELocationID": ["10.1016/j.jare.2022.10.017", "S2090-1232(22)00246-6"], "Journal": {"ISSN": "2090-1224", "JournalIssue": {"Volume": "51", "PubDate": {"Year": "2023", "Month": "Sep"}}, "Title": "Journal of advanced research", "ISOAbbreviation": "J Adv Res"}, "ArticleTitle": "Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma.", "Pagination": {"StartPage": "181", "EndPage": "196", "MedlinePgn": "181-196"}, "Abstract": {"AbstractText": ["Hyperactivated histone deacetylases (HDACs) act as epigenetic repressors on gene transcription and are frequently observed in human hepatocellular carcinoma (HCC). Although multiple pharmacological HDAC inhibitors (HDACis) have been developed, none is available in human HCC.", "To investigate the pharmacological effects of a fangchinoline derivative HL23, as a novel HDACi and its molecular mechanisms through TXNIP-mediated potassium deprivation in HCC.", "Both in vitro assays and orthotopic HCC mouse models were used to investigate the effects of HL23 in this study. The inhibitory activity of HL23 on HDACs was evaluated by in silico studies and cellular assays. Chromatin immunoprecipitation (ChIP) was conducted to confirm the regulation of HL23 on acetylation mark at TXNIP promoter. Genome-wide transcriptome analysis together with bioinformatic analysis were conducted to identify the regulatory mechanisms of HL23. The clinical significance of TXNIP and HDACs was evaluated by analysing publicly available database.", "HL23 exerted compatible HDACs inhibition potency as Vorinostat (SAHA) while had superior anti-HCC effects than SAHA and sorafenib. Both in vitro and in vivo studies showed HL23 significantly suppressed HCC progression and metastasis. HL23 significantly upregulated TXNIP expression via regulating acetylation mark (H3K9ac) at TXNIP promoter. TXNIP was responsible for anti-HCC activity of HL23 through mediating potassium channel activity. HDAC1 was predicted to be the target of HL23 and HDAC1<sup>low</sup>TXNIP<sup>high</sup> could jointly predict promising survival outcome of patients with HCC. Combination treatment with HL23 and sorafenib could significantly enhance sorafenib efficacy.", "Our study identified HL23 as a novel HDACi through enhancing acetylation at TXNIP promoter to trigger TXNIP-dependent potassium deprivation and enhance sorafenib efficacy in HCC treatment."], "CopyrightInformation": "Copyright \u00a9 2023. Production and hosting by Elsevier B.V."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong."}], "LastName": "Lu", "ForeName": "Yuanjun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Science, Guiyang 550014, China; Natural Products Research Centre, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China."}], "LastName": "Liu", "ForeName": "Yazhou", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Science, Guiyang 550014, China."}], "LastName": "Lan", "ForeName": "Junjie", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong."}], "LastName": "Chan", "ForeName": "Yau-Tuen", "Initials": "YT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong."}], "LastName": "Feng", "ForeName": "Zixin", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong."}], "LastName": "Huang", "ForeName": "Lan", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong. Electronic address: ckwang@hku.hk."}], "LastName": "Wang", "ForeName": "Ning", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Science, Guiyang 550014, China. Electronic address: weidongpan@gzcnp.cn."}], "LastName": "Pan", "ForeName": "Weidong", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chinese Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong. Electronic address: yfeng@hku.hk."}], "LastName": "Feng", "ForeName": "Yibin", "Initials": "Y"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Egypt", "MedlineTA": "J Adv Res", "NlmUniqueID": "101546952", "ISSNLinking": "2090-1224"}, "ChemicalList": [{"RegistryNumber": "9ZOQ3TZI87", "NameOfSubstance": "Sorafenib"}, {"RegistryNumber": "0", "NameOfSubstance": "Histones"}, {"RegistryNumber": "953592C3ZB", "NameOfSubstance": "fangchinoline"}, {"RegistryNumber": "58IFB293JI", "NameOfSubstance": "Vorinostat"}, {"RegistryNumber": "EC 3.5.1.98", "NameOfSubstance": "Histone Deacetylases"}, {"RegistryNumber": "52500-60-4", "NameOfSubstance": "Thioredoxins"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Carcinoma, Hepatocellular"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Sorafenib"}, {"QualifierName": ["metabolism", "therapeutic use"], "DescriptorName": "Histones"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Liver Neoplasms"}, {"QualifierName": [], "DescriptorName": "Acetylation"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Vorinostat"}, {"QualifierName": ["metabolism", "therapeutic use"], "DescriptorName": "Histone Deacetylases"}, {"QualifierName": ["metabolism", "therapeutic use"], "DescriptorName": "Thioredoxins"}], "CoiStatement": "Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Rebouissou S, Nault J-C. Advances in molecular classification and precision oncology in hepatocellular carcinoma. 2020;72:215\u201329.", "ArticleIdList": ["31954487"]}, {"Citation": "Lu Y, Chan Y-T, Tan H-Y, Li S, Wang N, Feng YJM. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. 2020;19:1\u201316.", "ArticleIdList": ["PMC7184703", "32340605"]}, {"Citation": "Liu K.-Y., Wang L.-T. Hsu S-HJC. Modification of epigenetic histone acetylation in hepatocellular carcinoma. 2018;10:8.", "ArticleIdList": ["PMC5789358", "29301348"]}, {"Citation": "Kanki K., Watanabe R., Le Thai N., Zhao C.-H., Naito K.J.C. HDAC9 is preferentially expressed in dedifferentiated hepatocellular carcinoma cells and is involved in an anchorage-independent. Growth. 2020;12:2734.", "ArticleIdList": ["PMC7598174", "32977608"]}, {"Citation": "Liu S-S, Wu F, Jin Y-M, Chang W-Q, Xu T-MJB, pharmacotherapy. HDAC11: a rising star in epigenetics. 2020;131:110607.", "ArticleIdList": ["32841898"]}, {"Citation": "Buurman R, G\u00fcrlevik E, Sch\u00e4ffer V, Eilers M, Sandbothe M, Kreipe H, et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. 2012;143:811\u201320.e15.", "ArticleIdList": ["22641068"]}, {"Citation": "Tian Y, Mok MT, Yang P, Cheng ASJC. Epigenetic activation of Wnt/\u03b2-catenin signaling in NAFLD-associated hepatocarcinogenesis. 2016;8:76.", "ArticleIdList": ["PMC4999785", "27556491"]}, {"Citation": "Tsai CL, Liu WL, Hsu FM, Yang PS, Yen RF, Tzen KY, et al. Targeting histone deacetylase 4/ubiquitin\u2010conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. 2018;67:586\u201399.", "ArticleIdList": ["28646552"]}, {"Citation": "Wang A.-G., Seo S.-B., Moon H.-B., Shin H.-J., Kim D.H., Kim J.-M., et al. Hepatic steatosis in transgenic mice overexpressing human histone deacetylase 1. Biochem Biophys Res Commun. 2005;330:461\u2013466.", "ArticleIdList": ["15796905"]}, {"Citation": "Han J., Ding L., Yuan B., Yang X., Wang X., Li J., et al. Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells. Nucleic Acids Res. 2006;34:3095\u20133106.", "ArticleIdList": ["PMC1475750", "16757575"]}, {"Citation": "Al-Yhya N., Khan M.F., Almeer R.S., Alshehri M.M., Aldughaim M.S., Wadaan M.A. Pharmacological inhibition of HDAC1/3-interacting proteins induced morphological changes, and hindered the cell proliferation and migration of hepatocellular carcinoma cells. Environ Sci Pollut Res Int. 2021;28:49000\u201349013.", "ArticleIdList": ["33929667"]}, {"Citation": "Qian Y.Y., Liu Z.S., Yan H.J., Yuan Y.F., Levenson A.S., Li K. Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma. Biomed Pharmacother. 2018;101:852\u2013859.", "ArticleIdList": ["29635894"]}, {"Citation": "Dang F., Wei W. Seminars in cancer biology. Elsevier; 2021. Targeting the acetylation signaling pathway in cancer therapy.", "ArticleIdList": ["PMC8423867", "33705871"]}, {"Citation": "Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MIJP, et al. Epigenetic therapy as a novel approach in hepatocellular carcinoma. 2015;145:103\u201319.", "ArticleIdList": ["25205159"]}, {"Citation": "Lu Y.S., Kashida Y., Kulp S.K., Wang Y.C., Wang D., Hung J.H., et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. 2007;46:1119\u20131130.", "ArticleIdList": ["17654699"]}, {"Citation": "A Salvador L, Luesch HJCdt. Discovery and mechanism of natural products as modulators of histone acetylation. 2012;13:1029\u201347.", "ArticleIdList": ["PMC3802541", "22594471"]}, {"Citation": "Yang W-Q, Zhou J, Feng Y, Cheung KW, Cheng AS-L. Enhancing the efficacy of liver cancer immunotherapy by specific inhibition of histone deacetylase 8. AACR; 2019."}, {"Citation": "Wang N., Pan W., Zhu M., Zhang M., Hao X., Liang G., et al. Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol. 2011;164:731\u2013742.", "ArticleIdList": ["PMC3188903", "21418191"]}, {"Citation": "Chen J.-C., Chan Y.-C., Hwang J.-H. Effects of tetrandrine and caffeine on cell viability and expression of mammalian target of rapamycin, phosphatase and tensin homolog, histone deacetylase 1, and histone acetyltransferase in glioma cells. Tzu Chi Med J. 2015;27:74\u201378."}, {"Citation": "Lan J., Wang N., Huang L., Liu Y., Ma X., Lou H., et al. Design and synthesis of novel tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma. Eur J Med Chem. 2017;127:554\u2013566.", "ArticleIdList": ["28109948"]}, {"Citation": "Wang N, Tan H-Y, Lu Y, Chan Y-T, Wang D, Guo W, et al. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. 2021;6:1\u201313.", "ArticleIdList": ["PMC7907082", "33633112"]}, {"Citation": "Grosdidier A., Zoete V., Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 2011;39:W270\u2013W277.", "ArticleIdList": ["PMC3125772", "21624888"]}, {"Citation": "Kim B, Hong JJCtimc. An overview of naturally occurring histone deacetylase inhibitors. 2014;14:2759\u201382.", "ArticleIdList": ["PMC6805157", "25487010"]}, {"Citation": "Lansigan F, Foss FMJD. Current and emerging treatment strategies for cutaneous T-cell lymphoma. 2010;70:273\u201386.", "ArticleIdList": ["20166766"]}, {"Citation": "Raoul J-L, Kudo M, Finn RS, Edeline J, Reig M, Galle PRJCtr. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. 2018;68:16\u201324.", "ArticleIdList": ["29783126"]}, {"Citation": "Kavanaugh S.A., White L.A., Kolesar J.M. Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health-Syst Pharm. 2010;67:793\u2013797.", "ArticleIdList": ["20479100"]}, {"Citation": "Sheth S, Bodnar J, Ghazalpour A, Thipphavong C, Tsutsumi S, Tward A, et al. Hepatocellular carcinoma in Txnip-deficient mice. 2006;25:3528\u201336.", "ArticleIdList": ["16607285"]}, {"Citation": "Chen Y, Ning J, Cao W, Wang S, Du T, Jiang J, et al. Research progress of TXNIP as a tumor suppressor gene participating in the metabolic reprogramming and oxidative stress of cancer cells in various cancers. 2020;10.", "ArticleIdList": ["PMC7609813", "33194655"]}, {"Citation": "De Marinis Y, Cai M, Bompada P, Atac D, Kotova O, Johansson ME, et al. Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney. 2016;89:342\u201353.", "ArticleIdList": ["26806835"]}, {"Citation": "Kuang Q., Purhonen P., Hebert H. Structure of potassium channels. Cell Mol Life Sci. 2015;72:3677\u20133693.", "ArticleIdList": ["PMC4565861", "26070303"]}, {"Citation": "Huang X, Jan LYJJoCB. Targeting potassium channels in cancer. 2014;206:151\u201362.", "ArticleIdList": ["PMC4107787", "25049269"]}, {"Citation": "Urrego D, Tomczak AP, Zahed F, St\u00fchmer W, Pardo LAJPTotRSBBS. Potassium channels in cell cycle and cell proliferation. 2014;369:20130094.", "ArticleIdList": ["PMC3917348", "24493742"]}, {"Citation": "Bachmann M, Li W, Edwards MJ, Ahmad SA, Patel S, Szabo I, et al. Voltage-gated potassium channels as regulators of cell death. 2020;8:1571.", "ArticleIdList": ["PMC7767978", "33381507"]}, {"Citation": "Bates EJAroc, biology d. Ion channels in development and cancer. 2015;31:231\u201347.", "ArticleIdList": ["26566112"]}, {"Citation": "Kondratskyi A, Kondratska K, Skryma R, Prevarskaya NJBeBA-B. Ion channels in the regulation of apoptosis. 2015;1848:2532\u201346.", "ArticleIdList": ["25450339"]}, {"Citation": "Lu J, Holmgren AJFRB, Medicine. The thioredoxin antioxidant system. 2014;66:75\u201387.", "ArticleIdList": ["23899494"]}, {"Citation": "Zaragoza-Campillo MA, Mor\u00e1n JJOm, longevity C. Reactive oxygen species evoked by potassium deprivation and staurosporine inactivate Akt and induce the expression of TXNIP in cerebellar granule neurons. 2017.", "ArticleIdList": ["PMC5358461", "28367274"]}, {"Citation": "Tsubaki H, Tooyama I, Walker DGJIjoms. Thioredoxin-Interacting protein (TXNIP) with focus on brain and neurodegenerative diseases. 2020;21:9357.", "ArticleIdList": ["PMC7764580", "33302545"]}, {"Citation": "Zhou R, Tardivel A, Thorens B, Choi I, Tschopp JJNi. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. 2010;11:136\u201340.", "ArticleIdList": ["20023662"]}, {"Citation": "Jiao D., Huan Y., Zheng J., Wei M., Zheng G., Han D., et al. UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP. Oncogene. 2019;38:5686\u20135699.", "ArticleIdList": ["31043707"]}, {"Citation": "Lee J.H., Jeong E.G., Choi M.C., Kim S.H., Park J.H., Song S.H., et al. Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Mol Cells. 2010;30:107\u2013112.", "ArticleIdList": ["20680488"]}, {"Citation": "Cho SY, Kim S, Son M-J, Rou WS, Kim SH, Eun HS, et al. Clinical significance of the thioredoxin system and thioredoxin-domain-containing protein family in hepatocellular carcinoma. 2019;64:123\u201336.", "ArticleIdList": ["30288659"]}, {"Citation": "Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. 2008;359:378\u201390.", "ArticleIdList": ["18650514"]}, {"Citation": "Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.-F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u2013390.", "ArticleIdList": ["18650514"]}, {"Citation": "Cheng A.-L., Kang Y.-K., Chen Z., Tsao C.-J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.", "ArticleIdList": ["19095497"]}, {"Citation": "Lachenmayer A., Toffanin S., Cabellos L., Alsinet C., Hoshida Y., Villanueva A., et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012;56:1343\u20131350.", "ArticleIdList": ["PMC3355195", "22322234"]}, {"Citation": "Ngamphaiboon N., Dy G.K., Ma W.W., Zhao Y., Reungwetwattana T., DePaolo D., et al. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Invest New Drugs. 2015;33:225\u2013232.", "ArticleIdList": ["25371323"]}, {"Citation": "Streubel G., Schrepfer S., Kallus H., Parnitzke U., Wulff T., Hermann F., et al. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Sci Rep. 2021;11:1\u201315.", "ArticleIdList": ["PMC8100298", "33953226"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "25"}, {"Year": "2022", "Month": "10", "Day": "28"}, {"Year": "2022", "Month": "10", "Day": "29"}, {"Year": "2023", "Month": "9", "Day": "4", "Hour": "6", "Minute": "42"}, {"Year": "2022", "Month": "11", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "11", "Day": "9", "Hour": "19", "Minute": "24"}, {"Year": "2022", "Month": "11", "Day": "9"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36351536", "PMC10491973", "10.1016/j.jare.2022.10.017", "S2090-1232(22)00246-6"]}}], "PubmedBookArticle": []}